



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/751595/2012

European Medicines Agency decision

P/0253/2012

of 30 November 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for spheroids of human autologous matrix-associated chondrocytes (EMA-001264-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0253/2012

of 30 November 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for spheroids of human autologous matrix-associated chondrocytes (EMA-001264-PIP01-12) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by co.don AG on 12 March 2012 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 November 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for spheroids of human autologous matrix-associated chondrocytes, implantation suspension, implantation, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for spheroids of human autologous matrix-associated chondrocytes, implantation suspension, implantation, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for spheroids of human autologous matrix-associated chondrocytes, implantation suspension, implantation, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to co.don® AG, Warthestraße 21, 14513 – Teltow, Germany.

Done at London, 30 November 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/557586/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001264-PIP01-12

Scope of the application

Active substance(s):

Spheroids of human autologous matrix-associated chondrocytes

Condition(s):

Treatment of cartilage disorders

Pharmaceutical form(s):

Implantation suspension

Route(s) of administration:

Implantation

Name / corporate name of the PIP applicant:

co.don AG

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, co.don AG submitted for agreement to the European Medicines Agency on 12 March 2012 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 16 April 2012.

Supplementary information was provided by the applicant on 17 August 2012.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
 - to grant a deferral in accordance with Article 21 of said Regulation
 - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 9 November 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of cartilage disorders

The waiver applies to:

- the paediatric population from birth to closure of the epiphyses as determined radiologically;
- for implantation suspension for implantation;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition: treatment of cartilage disorders

2.1.1. Indication(s) targeted by the PIP

Treatment of cartilage disorders

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From closure of the epiphyses as determined radiologically to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Implantation suspension for implantation

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	1	Study 1) (cod 16 HS 17 paed) Prospective non-interventional investigation to evaluate the long-term safety and linked efficacy of the three-dimensional autologous chondrocyte implantation product in paediatric patients from closure of the epiphyses to less than 18 years of age treated with the product until December 2011.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2018
Deferral for one or more studies contained in the paediatric investigation plan:	Yes